Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label compassionate use program in cystic fibrosis patients with non-tuberculous mycobacteria (NTM) Infection

Trial Profile

A prospective, open-label compassionate use program in cystic fibrosis patients with non-tuberculous mycobacteria (NTM) Infection

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Cystic fibrosis; Nontuberculous mycobacterium infections
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
    • 16 Jul 2018 According to an AIT Therapeutics media release, data from the compassionate use study was presented at the 3rd Annual World Bronchiectasis Conference.
    • 27 Jun 2018 According to an AIT Therapeutics media release, data from compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top